IGF-1 LR3
Also known as: Long R3 IGF-1
IGF-1 LR3 is an 83-amino-acid modified IGF-1 analog with a 13-residue N-terminal extension (MFPAMPLSSLFVN) and an Arg-3 substitution. These modifications reduce binding to IGF binding proteins (IGFBPs), extending effective half-life and increasing tissue bioavailability relative to native IGF-1. It is a research/cell-culture reagent and is NOT FDA-approved for any human use. Do not confuse with mecasermin (Increlex), which is recombinant human IGF-1 and IS FDA-approved for severe primary IGF-1 deficiency.
Pricing for IGF-1 LR3
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
COAs for IGF-1 LR3
30 third-party tests across 11 vendors. Each card links to the full report.
For
IGF-1 LR3
by Ion Peptide· batch IGF1-052026
For
IGF-1 LR3
by Peptide Supply Co.· batch IG105192026
For
IGF-1 LR3
by Amino Club· batch IGF0001
For
IGF-1 LR3
by Ion Peptide· batch IGF1-03102026
For
IGF-1 LR3
by Peptide Supply Co.· batch GLR31031026
For
IGF-1 LR3
by Mile High Compounds· batch IGF-001-MH-02
For
IGF-1 LR3
by Skye Peptides· batch IGF25-1-003
For
IGF-LR3
by Simple Peptide· batch IGFR12172025-J
For
IGF-1 LR3
by ZLZ peptides· batch cmojgromn00539grxzzwqeri4
For
IGF-1 LR3
by Ion Peptide· batch IL-L-1025
For
IGF-1 LR3
by Ion Peptide· batch IL-1025
For
IGF-LR3
by Simple Peptide· batch IGLR09222025-J
For
IGF-1 LR3
by Profound Aminos· batch cmojb86a401h8kirxvxbas7o4
For
IGF-1 LR3
by Verified Peptides· batch 09-25-0301C
For
IGF-1 LR3
by Hydro Research Peptides· batch HYD-IGFLR3-2508-02
For
IGF-1 LR3
by Simple Peptide· batch IGFLR301072025-J
For
IGF-LR3
by Simple Peptide· batch 2530301
For
IGF-1 LR3
by Skye Peptides· batch IGF25-1-001
For
IGF-1 LR-3
by Verified Peptides· batch 10-24-0201B
For
IGF-1 LR3
by Verified Peptides· batch 08-24-0101A
For
IGF-1 LR3
by Peptide Tech· batch I3-001
For
IGF-1 LR3
by Ion Peptide· batch IGF1-05042026
For
IGF-1 LR3
by Moglabs· batch IGF102
Purity not on file
For
IGF-LR3
by Skye Peptides· batch IGF26-01-001
13 citations indexed for IGF-1 LR3
Study · 2026
Intact Proteoform Analysis by Capillary Electrophoresis-Mass Spectrometry. Are We There Yet?
Mass spectrometry (MS)-based top-down proteomics (TDP) has emerged as a powerful tool for characterizing proteoforms to advance both fundamental and translational research. TDP requires high-efficiency liquid-phase separation, high-resolution MS, and tandem MS.
review · 2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Therapeutic peptides are short chains of amino acids used to treat metabolic and endocrine conditions such as obesity and type 2 diabetes.
animal · 2025
Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration
Peripheral nerve injuries lead to significant functional deficits, with no treatment achieving complete recovery. Autologous nerve grafting remains the gold standard, but it is limited by donor site morbidity. Artificial nerve conduits have been developed but have not matched the outcomes of autologous grafts.
animal · 2025
IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep
Insulin-like growth factor-1 (IGF-1) and insulin are important fetal anabolic hormones.
Study · 2025
Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice
Background Insulin-like growth factor-1 (IGF-1) promotes neurogenesis, cell survival, and glial function, making it a promising candidate therapy in Alzheimer's disease (AD). Objective Long arginine 3-IGF-1 (LR3-IGF-1) is a potent IGF-1 analogue.
Study · 2025
Anti-inflammatory myeloid angiogenic cells (MIL4-MACs) attenuate angiotensin II‒induced heart failure in mice
For cell therapy to treat heart failure, therapeutic cells should possess the abilities to promote vascularization, remodel tissues, and reduce inflammation. Previously we clarified that CD14 + -derived myeloid angiogenic cells (MACs) possessed an angiogenic ability.